Who
Timothy P. Kelly
Chief Technology Officer
Company insider
Files Form 4 as: Chief Technology Officer, Caribou Biosciences; Chief Operating Officer, Leverage Shares 2X Long FIX Daily ETF.
In numbers
- Trades disclosed
- 47
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $356K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 14 Dec 2018
- Last trade
- 25 Feb 2026
- Last filed
- 27 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Feb 2026filed 27 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $12K6,228 at $1.93 | filing |
| 25 Feb 2026filed 27 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $12K6,228 at $1.93 | filing |
| 24 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $6,1683,147 at $1.96 | filing |
| 24 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $6,1683,147 at $1.96 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —202,500 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —202,500 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 8 Jan 2024filed 9 Jan 2024 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 24 Feb 2022filed 28 Feb 2022 | FIXX Leverage Shares 2X Long FIX Daily ETFoption or derivative | SEC FORM 4 Code A | —28,200 at $0.00 | filing |
| 24 Feb 2022filed 28 Feb 2022 | FIXX Leverage Shares 2X Long FIX Daily ETFoption or derivative | SEC FORM 4 Code A | —4,800 at $0.00 | filing |
| 5 Jan 2022filed 12 Jan 2022 | FIXX Leverage Shares 2X Long FIX Daily ETF | SEC FORM 4 Sold | $5,3151,406 at $3.78 | filing |
| 1 Jan 2022filed 12 Jan 2022 | FIXX Leverage Shares 2X Long FIX Daily ETFoption or derivative | SEC FORM 4 Code M | —3,630 at $0.00 | filing |
| 1 Jan 2022filed 12 Jan 2022 | FIXX Leverage Shares 2X Long FIX Daily ETF | SEC FORM 4 Code M | —3,630 | filing |
| 3 Sep 2021filed 8 Sep 2021 | FIXX Leverage Shares 2X Long FIX Daily ETF | SEC FORM 4 Sold | $41654 at $7.70 | filing |
| 7 Apr 2021filed 9 Apr 2021 | FIXX Leverage Shares 2X Long FIX Daily ETFoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Mar 2021filed 8 Sep 2021 | FIXX Leverage Shares 2X Long FIX Daily ETF | SEC FORM 4 Sold | $70K6,232 at $11.16 | filing |
| 1 Mar 2021filed 3 Mar 2021 | FIXX Leverage Shares 2X Long FIX Daily ETF | SEC FORM 4 Code M | $13K2,000 at $6.63 | filing |
News
Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Has Average Price Target of $5.50CRBU · dailypolitical.com · 19 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)CRBU · tickerreport.com · 14 Oct 2026Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 TrialCRBU · medicaldaily.com · 10 Oct 2026
0 headlines in the last 90 days name Timothy P. Kelly; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.